Regulations.gov document
COVID–19: Developing Drugs and Biological Products for Treatment or Prevention; Guidance…
Notice · FDA-2020-D-1370 · posted May 12, 2021
Key facts
| Document ID | FDA-2020-D-1370-0022 |
|---|---|
| Title | COVID–19: Developing Drugs and Biological Products for Treatment or Prevention; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2020-D-1370 |
| Posted | May 12, 2021 |
| Federal Register citation | 86 FR 26050 |
| FR document number | 2021-10061 |
| Comment period opens | May 12, 2021 |
| Effective date | May 12, 2021 |
At a glance
- 1–9 Pages
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: